Company intelligence / Profile preview

PanRu Biotechnology

Tianjin, China

Ownership: Private
Development stage: Other

Overview

PanRu Biotechnology is a biotech company based in Tianjin, China, focused on developing therapeutic mRNA vaccines for cancer. The company's lead program, PRBT001, is an mRNA vaccine targeting prostate cancer currently in pre-clinical/early clinical development stages. PanRu licenses CanSino Biologics' ISL-3C-LNP platform for global R&D, manufacturing, and commercialization.

Therapeutic areas: Oncology
Modalities: mRNA-based drugs
Industry: Biotech

Drug pipeline

1 asset

PRBT001

Preclinical

Partnerships

CanSino Biologics

Beyond the preview

Go deeper on PanRu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanRu Biotechnology.

Explore the full profile